INTAS THIRD PARTY SALES 2005 S.L.U. – Trademark Portfolio

Entity Type: 99

INTAS THIRD PARTY SALES 2005 S.L.U. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include OPBIZTA, RACUVIZEE, and REXATILUX.

WORLD TRADE CENTER, MOLL DE BARCELONA,

S/N, EDIFIC I EST, 6ª PLANTA E-08039 BAR

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

REXATILUX
REXATILUX
Registered 2021
OPBIZTA
OPBIZTA
Registered 2021
RACUVIZEE
RACUVIZEE
Registered 2021

Trademark Classifications

INTAS THIRD PARTY SALES 2005 S.L.U.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does INTAS THIRD PARTY SALES 2005 S.L.U. have?

INTAS THIRD PARTY SALES 2005 S.L.U. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.

What trademark classes does INTAS THIRD PARTY SALES 2005 S.L.U. file in?

INTAS THIRD PARTY SALES 2005 S.L.U. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are INTAS THIRD PARTY SALES 2005 S.L.U.'s most well-known trademarks?

INTAS THIRD PARTY SALES 2005 S.L.U.'s registered trademark portfolio includes well-known marks such as OPBIZTA, RACUVIZEE, and REXATILUX. These are among 3 currently registered trademarks in the portfolio.

What is INTAS THIRD PARTY SALES 2005 S.L.U.'s trademark registration success rate?

INTAS THIRD PARTY SALES 2005 S.L.U. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.